Jack Higgins, Chief Scientific Officer of Immunome Inc. (NASDAQ:IMNM), filed a Form 4 on September 15, 2026, reporting multiple transactions in common stock and employee stock options dated September 11, 2026.

Key Highlights

  • Option exercise: Higgins exercised 18,000 employee stock options at an exercise price of $1.35 per share on September 11, 2026.
  • Open-market sale: 13,200 shares of common stock were sold at $25.32 per share, pursuant to a Rule 10b5-1 trading plan adopted December 19, 2025.
  • Gift of shares: 8,800 shares were disposed of via a gift transaction (code G) at $0 on September 11, 2026.
  • Direct beneficial ownership following transactions: 56,250 shares of common stock held directly, plus 1,000 shares each in three custodial accounts for children held indirectly.
  • Remaining derivative securities: 133,840 employee stock options (right to buy) remain directly owned following the reported transactions, with an exercise price of $1.35 and expiration date of June 23, 2032.

Immunome CSO Jack Higgins Reports Option Exercise, Share Sale, and Gift

According to the filing, Jack Higgins, serving as Chief Scientific Officer of Immunome Inc., executed three transactions in the company's common stock on September 11, 2026. He first exercised 18,000 employee stock options at an exercise price of $1.35 per share, acquiring those shares with an acquisition code of M. This brought his directly held beneficial ownership to 78,250 shares prior to the subsequent dispositions reported on the same date.

The filing discloses that Higgins then sold 13,200 shares at a price of $25.32 per share, reducing his direct holdings to 65,050 shares. The filing states that "the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025." A separate transaction on the same date recorded the disposition of 8,800 shares as a gift at $0, bringing direct beneficial ownership to 56,250 shares.

The filing also reports that Higgins holds 1,000 shares indirectly in each of three custodial accounts for his children under the Uniform Transfer to Minors Act. The filing notes that Higgins "disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose." Regarding the remaining 133,840 employee stock options, the filing explains that 25% vested on May 1, 2023, with one-thirty-sixth of the remaining shares vesting monthly thereafter, subject to continuous service.

What Was Disclosed

The Form 4 covers an option exercise of 18,000 shares at $1.35, a sale of 13,200 shares at $25.32 under a pre-existing 10b5-1 plan, and a gift of 8,800 shares, all on September 11, 2026, by Immunome's Chief Scientific Officer.